Diet and Nutrition
Creatine supplementation causes liver inflammation in mice but not rats
Published in Hepatitis Weekly, October 27th, 2003
"Creatine monohydrate (CrM) supplementation appears to be relatively safe based on data from short-term and intermediate-term human studies and results from several therapeutic trials. The purpose of the current study was to characterize pathological changes after intermediate-term and long-term CrM supplementation in mice [healthy control and SOD1 (G93A) transgenic] and rats (prednisolone and nonprednisolone treated)," according to researchers in Canada.
"Histological assessment (18-20 organs/tissues) was performed on G93A mice after 159 days and in Sprague-Dawley rats after 365 days...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-10-27)
More Articles from Hepatitis Weekly
- Neuroscience
MARS alleviates neurological progression in liver disease-related coma - Transplantation
Interferon therapy prior to liver transplant curbs hepatitis C recurrence - Liver Cirrhosis
Suppression subtractive hybridization characterizes the genetics of cirrhosis - Virology
The 5' untranslated region of GB virus C highlights genotypic differences - AIDS Research
U.S.-Russian initiative to intensify cooperation in fight against disease - Adverse Drug Effects
Apoptosis precedes necrosis in acetaminophen-induced liver injury - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
